Sanofi (SNY) Tax Provisions (2009 - 2026)
Sanofi (SNY) posted Tax Provisions of -$524.2 million for Q2 2026, down 6.61% sequentially from -$491.7 million in Q1 2026, and down 101.35% YoY from $38.7 billion in Q2 2025.
Sanofi (SNY) Tax Provisions (2009 - 2026) Analysis & Trends
Sanofi has reported Tax Provisions for 18 years, with the latest figure at -$524.2 million in Q2 2026.
- Quarterly Tax Provisions fell 101.35% year-over-year to -$524.2 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$3.9 billion (down 37.52% YoY) and the FY2025 annual result came in at $1.2 billion, down 5.63% from the prior year.
- Tax Provisions retreated to -$524.2 million in Q2 2026 per SNY's latest filing, from -$491.7 million in the prior quarter.
- Over five years, Tax Provisions peaked at -$113.0 million in Q1 2024 and troughed at -$1.6 billion in Q3 2025.
- A 5-year average of -$657.5 million and a median of -$515.1 million in 2025 frame the typical range for Tax Provisions.
- The sharpest annual moves came in 2024 and 2025: Tax Provisions surged 77.07% in 2024, then sank 347.82% in 2025.
- Over 5 years, Tax Provisions stood at -$1.1 billion in 2022, then gained by 2.14% to -$1.1 billion in 2023, then dropped by 17.58% to -$1.3 billion in 2024, then gained by 5.63% to -$1.2 billion in 2025, then soared by 56.82% to -$524.2 million in 2026.
- According to Business Quant data, Tax Provisions over the past three periods registered -$524.2 million, -$491.7 million, and -$1.2 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Johnson & Johnson | 652.20 Bn | 631.44 Bn | 17.26 Bn | 1.21 Bn |
| 2 | AbbVie | 469.51 Bn | 462.94 Bn | 12.70 Bn | 662.00 Mn |
| 3 | Merck | 376.81 Bn | 369.67 Bn | 12.21 Bn | 654.00 Mn |
| 4 | Novartis Ag | 303.04 Bn | 295.35 Bn | 11.24 Bn | 1.01 Bn |
| 5 | Astrazeneca | 257.61 Bn | 252.71 Bn | 12.86 Bn | 291.00 Mn |
| 6 | Amgen | 237.37 Bn | 223.38 Bn | 7.24 Bn | 393.00 Mn |
| 7 | Gilead Sciences | 181.73 Bn | 178.55 Bn | 6.22 Bn | 242.00 Mn |
| 8 | Pfizer | 159.66 Bn | 147.96 Bn | 10.94 Bn | -407.00 Mn |
| 9 | Gsk | 106.24 Bn | 102.07 Bn | 8.24 Bn | 266.99 Mn |
| 10 | Sanofi | 55.07 Bn | 47.69 Bn | 10.79 Bn | -524.23 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -524.23 Mn |
| Mar 31, 2026 | -491.71 Mn |
| Dec 31, 2025 | -1.21 Bn |
| Sep 30, 2025 | -1.63 Bn |
| Jun 30, 2025 | -260.35 Mn |
| Mar 31, 2025 | -505.96 Mn |
| Dec 31, 2024 | -1.29 Bn |
| Sep 30, 2024 | -751.18 Mn |
| Jun 30, 2024 | -296.14 Mn |
| Mar 31, 2024 | -112.98 Mn |
| Dec 31, 2023 | -1.09 Bn |
| Sep 30, 2023 | -612.88 Mn |
| Jun 30, 2023 | -295.10 Mn |
| Mar 31, 2023 | -492.66 Mn |
| Dec 31, 2022 | -1.12 Bn |
| Sep 30, 2022 | -605.97 Mn |
| Jun 30, 2022 | -173.93 Mn |
| Mar 31, 2022 | -372.62 Mn |
| Dec 31, 2021 | -1.78 Bn |
| Sep 30, 2021 | -714.65 Mn |